1. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol 1995; 17: 1–54.
2. Weiss GB. Metabolism and actions of CDPcholine as an endogenous compound and administered exogenously as citicoline. Life Sci 1995; 56: 637–60.
3. D'Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neural Res 1995; 17: 281–4.
4. Rao AM, Hatcher JF, Dempsey RJ. CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. J Neurosci Res 1999; 58: 697–705.
5. Dinsdale JR, Griffiths GK, Rowlands C et al. Pharmacokinetics of 14C CDP-choline. Arzneimittel-forschung 1983; 33: 1066–70.
6. Agut J, Font E, Sacrist6n A, Ortiz JA. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline. Arzneimittelforschung 1983; 33: 1048–50.
7. G-Coviella IL, Wurtman RJ. Enhancement by cytidine of membrane phospholipid synthesis. J Neurochem 1992; 59: 338–43.
8. Lopez-Coviella I, Agut J, Savci V et al. Evidence that 5'-cytidinediphosphochoIine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. J Neurochem 1995; 65: 889–94.
9. Gimenez R, Soler S, Aguilar J. Cytidine diphosphatecholine administration activates brain cytidine triphosphate: phosphocholine cytidylyltransferase in aged rats. Neurosci Lett 1999; 273: 163–6.
10. Babb SM, Appelmans KE, Renshaw PF et al. Differential effect of CDP-choline on brain cytosoliccholine levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology (Berl) 1996; 127: 88–94.
11. Babb SM, Wald LL, Cohen BM et al. Chronic citicoline increases phosphodiesters in thebrains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl) 2002; 161: 248–54.
12. de la Morena E. Efficacy of CDP-choline in the treatment of senile alterations in memory. Ann N Y Acad Sci 1991; 640: 233–6.
13. Amenta F, Di Tullio MA, Tomassoni D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin Exp Hypertens 2002; 24: 697–713.
14. Plataras C, Tsakiris S, Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na(+), K(+)-ATPase in adult rats. Clin Biochem 2000; 33: 351–7.
15. Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem 2002; 80: 12–23.
16. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002; 70: 133–9.
17. Mayes PA. Metabolism of acylglycerols and sphingolipids. In: Murray RK, Mayes PA, eds. Harper's Biochemistry. 25th ed. Norwalk, CT: Appleton & Lange; 2000.
18. Rao AM, Hatcher JF, Dempsey RJ. Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res 2001; 893: 268–72.
19. Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res 2003; 73: 308–15.
20. Jayadev S, Linardic CM, Hannun YA. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha. J Biol Chem 1994; 269: 5757–63.
21. Nitta A, Itoh A, Hasegawa T, Nabeshima T. Beta-amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 1994; 170: 63–6.
22. Nitta A, Fukuta T, Hasegawa T, Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 1997; 73: 51–7.
23. Alvarez XA, Sampedro C, Lozano R, Cacabelos R. Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Methods Find Exp Clin Pharmacol 1999; 21: 535–40.
24. Wang CS, Lee RK. Choline plus cytidine stimulate phospholipid production, and the expression and secretion of amyloid precursor protein in rat PC 12 cells. Neurosci Lett 2000; 283: 25–8.
25. Petkov VD, Stancheva SL, Tocuschieva L, Petkov W. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen Pharmacol 1990; 21: 71–5.
26. Martinet M, Fonlupt P, Pacheco H. Effects of cytidine-5' diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch Int Pharmacodyn Ther 1979; 239: 52–61.
27. Martinet M, Fonlupt P, Pacheco H. Interaction of CDP-choline with synaptosomal transport of biogenic amines and their precursors in vitro and in vivo in the rat corpus striatum. Experientia 1978; 34: 1197–9.
28. Lopez I, Coviella G, Agut J, Wurtman RJ. Effect of cytidine(5')diphosphocholine (CDPcholine) on the total urinary excretion of 3-methoxy-4-hydroxyphenyl-glycol (MHPG) by rats and humans. J Neural Transm 1986; 66: 129–34.
29. Agut J, Coviella IL, Wurtman RJ. Cytidine(5')diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine. Neuropharmacology 1984; 23: 1403–6.
30. Adibhatla RM, Hatcher JF, Dempsey RJ. Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 2001; 32: 2376–81.
31. Baskaya MK, Dogan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg 2000; 92: 448–52.
32. Aronowski J, Strong R, Grotta JC. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. Neurol Res 1996; 18: 570–4.
33. Mykita S, Golly F, Dreyfus H et al. Effect of CDP-choline on hypocapnic neurons in culture. J Neurochem 1986; 47: 223–1.
34. Drago F, Mauceri F, Nardo L et al. Effects of cytidine-diphosphocholine on acetylcholinemediated behaviors in the rat. Brain Res Bull 1993; 31: 485–9.
35. Petkov VD, Kehayov RA, Mosharrof AH et al. Effects of cytidine diphosphate choline on rats with memory deficits. Arzneimittelforschung 1993; 43: 822–8.
36. Bruhwyler J, Liegeois JF, Geczy J. Facilitatory effects of chronically administered citicoline on learning and memory processes in the dog. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 115–28.
37. Andersen M, Overgaard K, Meden P et al. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 1999; 30: 1464–71.
38. Shuaib A, Yang Y, Li Q. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp Neurol 2000: 161: 733–9.
39. Tazaki Y, Sakai F, Otomo E et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988; 19: 211–6.
40. Agnoli A, Bruno G, Fioravanti M et al. Therapeutic approach to senile memory impairment: a double-blind clinical trial with CDP choline. In: Wurtman RJ, Corkin S, Growden JH, eds. Alzheimer's Disease: Proceedings of the Fifth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Boston, MA: Birkhauser; 1989: 649–54.
41. Spiers PA, Myers D, Hochanadel GS et al. Citicoline improves verbal memory in aging. Arch Neurol 1996; 53: 441–8.
42. Franceschi M, Smirne S, Canal N. Treatment of clinical signs and EEC patterns in patients with "organic brain syndrome." Clin Trials J 1982; 19: 74–84.
43. Cacabelos R, Caamano J, Gomez MJ et al. Therapeutic effects of CDP-choline in Alzheimer's disease. Ann N Y Acad Sci 1996; 777: 399–403.
44. Gannushkina IV. Pathogenesis of traumatic brain edema. In: Mchedlishvili G, et al, eds. Brain Edema, A Pathogenic Analysis. Budapest: Akademiai Kiado; 1986: 290–2.
45. Maldonado VC, Perez JB, Escario JA. Effects of CDP-choline on the recovery of patients with head injury. J Neurol Sci 1991; 103: S15–8.
46. Leon-Carrion J, Dominguez-Roldan JM, Murillo Cabezas F et al. The role of citicoline in neuropsychological training after traumatic brain injury. NeuroRehabilitation 2000; 14: 33–40.
47. Levin HS. Treatment of postconcussional symptoms with CDP-choline. J Neurol Sci 1991; 103: S39–42.
48. Caamaco J, Gymez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol 1994; 16: 211–8.
49. Alvarez XA, Mouzo R, Pichel V et al. Doubleblind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol 1999; 21: 633–44.
50. Cacabelos R, Alvarez XA, Franco-Maside A et al. Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia. Ann N Y Acad Sci 1993; 695: 321–3.
51. Grieb P, Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J Neurosci Res 2002; 67: 143–8.
52. Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma: III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Opthalmol 1982; 100: 135–46.
53. Paris! V, Manni G, Colacino G, Bucci MG. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999; 106: 1126–34.
54. Rejdak R, Toczolowski J, Solski J et al. Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Res 2002; 34: 146–9.
55. Campos EC, Schiavi C, Benedetti P et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol 1995; 233: 307–12.
56. Porciatti V, Schiavi C, Benedetti P et al. Cytidine5'-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr Eye Res 1998; 17: 141–8.
57. Agnoli A, Ruggieri S, Denaro A, Bruno G. New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 1982; 8: 289–96.
58. Grau T, Romero A, Sacristan A, Ortiz JA. CDP-choline: acute toxicity study. Arzneimittelforschung 1983; 33: 1033–4.
59. Romero A, Grau T, Sacristan A, Ortiz JA. Study of subacute toxicity of CDP-choline after 30 days of oral administration to rats. Arzneimittelforschung 1983; 33: 1035–8.
60. Romero A, Grau T, Sacristan A, Ortiz JA. CDP-choline: 6-month study on toxicity in dogs. Arzneimittelforschung 1983; 33: 1038–42.
61. Dinsdale JR, Griffiths GK, Castello J et al. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. Arzneimittelforschung 1983; 33: 1061–5.
62. Lozano Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung 1983; 33: 1073–80.